journal article·2022-11-08Open access

Developing of SiO2 Nanoshells Loaded with Fluticasone Propionate for Potential Nasal Drug Delivery: Determination of Pro-Inflammatory Cytokines through mRNA Expression

Yasir Mehmood, Hira Shahid, Md Abdur Rashid, Yahya Alhamhoom, Mohsin Kazi

Abstract

Mesoporous Silica Nanoparticles (MSN) are porous inorganic materials that have been extensively used for drug delivery due to their special qualities, such as biocompatibility, biodegradability, and non-toxicity. MSN is a promising drug delivery system to enhance the efficacy and safety of drug administration in nasal diseases like chronic rhinitis (CR). In this study, we used the sol-gel technique for MSN synthesis and incorporate fluticasone propionate (FP) for intranasal drug administration for the treatment of chronic rhinitis (CR). In order to confirm the particle size, shape, drug release, and compatibility, various instruments were used. MSN was effectively prepared with average sizes ranging between 400 ± 34 nm (mean ± SD) as measured by dynamic light scattering (DLS), while zeta potential verified in all cases their positive charged surface. To investigate MSN features, the Fourier transform infrared spectrometer (FTIR), scanning electron microscopy (SEM), transmission electron microscope (TEM), thermal analysis, X-ray diffraction (XRD), and nitrogen adsorption/desorption measurement were used. The loaded compound was submitted to in vitro dissolution tests, and a remarkable dissolution rate improvement was observed compared to the crystalline drug in both pH conditions (1.2 and 7.4 pH). By using an MTT assay cell viability was assessed. The expression levels of the anti-inflammatory cytokines IL-4 and IL-5 were also measured using mRNA extraction from rat blood. Other characterizations like acute toxicity and hemolytic activity were also performed to confirm loaded MSN safety. Loaded MSN was incorporated in nasal spray prepared by using innovator excipients including poloxamer. After this, its nasal spray’s physical characteristics were also determined and compared with a commercial product (Ticovate).
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Sinusitis and nasal conditions · Ocular Surface and Contact Lens

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad P.O. Box 38000, Pakistan

Department of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad P.O. Box 38000, Pakistan

Department of Pharmaceutics, College of Pharmacy, King Khalid University, Guraiger, Abha 62529, Saudi Arabia

Pharmacy Discipline, Faculty of Health, School of Clinical Sciences, Queensland University of Technology, Brisbane, QLD 4000, Australia

Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

Funding

Deanship of Scientific Research at King Khalid University for funding this work through group (large) research program

References (52)

Show source-provided references
1. Prevalence and Risk Factor of Chronic Rhinosinusitis and the Impact on Quality of Life in Students of the Medical Faculty Christian University of Indonesia in 201810.22270/jddt.v11i3-S.4846 ↗
2. Management of chronic rhinosinusitis in CF10.1016/S1569-1993(09)60005-9 ↗
3. Efficacy of functional endoscopic sinus surgery for symptoms in chronic rhinosinusitis with or without polyposis10.1016/S1808-8694(15)30062-8 ↗
4. Emerging biologics for the treatment of chronic rhinosinusitis10.1586/1744666X.2015.1010517 ↗
5. Oral steroid therapy in chronic rhinosinusitis with and without nasal polyposis10.1007/s11882-012-0329-5 ↗
6. Risks and management of long-term corticosteroid use in chronic rhinosinusitis10.1097/MOO.0000000000000421 ↗
7. Chronic rhinosinusitis: The rationale for current treatments10.1080/1744666X.2016.1220833 ↗
8. A systematic review of the use of intranasal steroids in the treatment of chronic rhinosinusitis10.1016/j.otohns.2008.05.628 ↗
9. Chronic rhinosinusitis management beyond intranasal steroids and saline solution irrigations10.2500/aap.2015.36.3866 ↗
10. Topical corticosteroids in chronic rhinosinusitis: A randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray
11. Safety and efficacy of a bioabsorbable fluticasone propionate-eluting sinus dressing in postoperative management of endoscopic sinus surgery: A randomized clinical trial10.1002/alr.21963 ↗
12. Formulation and nebulization of fluticasone propionate-loaded lipid nanocarriers10.1016/j.ijpharm.2015.07.008 ↗
13. Drug solubility: Importance and enhancement techniques
14. Solubility enhancement techniques
15. Orally deliverable strategy based on microalgal biomass for intestinal disease treatment10.1126/sciadv.abi9265 ↗
16. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review
17. Manganese-enhanced MRI of rat brain based on slow cerebral delivery of manganese (II) with silica-encapsulated MnxFe1–xO nanoparticles10.1002/nbm.2932 ↗
18. Nanoparticles: A personal experience for formulating poorly water soluble drugs10.1016/j.jconrel.2009.10.006 ↗
19. Nanoparticle formulation increases oral bioavailability of poorly soluble drugs: Approaches, experimental evidences and theory10.2174/157341305774642939 ↗
20. Magnetically stimulated drug release using nanoparticles capped by self-assembling peptides10.1021/acsami.9b13614 ↗
21. Core/shell nanoparticles in biomedical applications10.1016/j.cis.2013.12.008 ↗
22. Bionanotechnology based on silica nanoparticles10.1002/med.20003 ↗
23. Mesoporous silica nanoparticles in biomedical applications10.1039/c1cs15246g ↗
24. Phytochemical-loaded mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery10.1016/j.ijpharm.2016.09.042 ↗
25. Mesoporous silica nanoparticles for pulmonary drug delivery10.1016/j.addr.2021.113953 ↗
26. Nasal pH measurement: A reliable and repeatable parameter10.1046/j.1365-2273.1999.00223.x ↗
27. Mesoporous silica nanoparticles for drug delivery10.1002/adfm.201902634 ↗
28. Mesoporous silica nanoparticles in drug delivery and biomedical applications10.1016/j.nano.2014.09.014 ↗
29. Facile Synthesis of Mesoporous Silica Nanoparticles Using Modified Sol-Gel Method: Optimization and In Vitro Cytotoxicity Studies
30. Hybrid drug carriers with temperature-controlled on–off release: A simple and reliable synthesis of PNIPAM-functionalized mesoporous silica nanoparticles10.1016/j.reactfunctpolym.2015.11.006 ↗
31. DDSolver: An add-in program for modeling and comparison of drug dissolution profiles10.1208/s12248-010-9185-1 ↗
32. Development and characterization of pH-responsive polyethylene glycol-co-poly(methacrylic acid) polymeric network system for colon target delivery of oxaliplatin: Its acute oral toxicity study10.1002/adv.21840 ↗
33. Preparation and characterization of alginate-PVA-based semi-IPN: Controlled release pH-responsive composites10.1007/s00289-017-2079-y ↗
34. Thermosensitive injectable hydrogel containing carboplatin loaded nanoparticles: A dual approach for sustained and localized delivery with improved safety and therapeutic efficacy10.1016/j.jddst.2020.101817 ↗
35. Equator Assessment of Nanoparticles Using the Design-Expert Software
36. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays10.1016/0022-1759(83)90303-4 ↗
37. In-vitro cytotoxicity activity of Solanum nigrum extract against Hela cell line and Vero cell line
38. Allergic Rhinitis in Rats Is Associated with an Inflammatory Response of the Hippocampus10.1155/2018/8750464 ↗
39. Acute toxicity studies of a novel excipient arabinoxylan isolated from Ispaghula (Plantago ovata) husk10.3109/01480545.2014.956219 ↗
40. Silica Content and Structure from Corncob Ash with Various Acid Treatment (HCl, HBr, and Citric Acid)10.20884/1.jm.2017.12.2.382 ↗
41. Surface functionalization of SBA-15 particles for amoxicillin delivery10.1016/j.micromeso.2012.02.037 ↗
42. Outside-in stepwise functionalization of mesoporous silica nanocarriers for matrix type sustained release of fluoroquinolone drugs10.1039/C4TB02073A ↗
43. Solid state characterization of mometasone furoate anhydrous and monohydrate forms10.1002/jps.20470 ↗
44. Structure and properties of titania reinforced nano-hydroxyapatite/gelatin bio-composites for bone graft materials10.1016/j.ceramint.2011.07.045 ↗
45. Organic/inorganic bioactive materials part IV: In vitro assessment of bioactivity of gelatin-calcium phosphate silicate/wollastonite hybrids10.2478/s11532-009-0142-8 ↗
46. Silica–gelatin bio-hybrid and transparent nano-coatings through sol–gel technique10.1016/j.matchemphys.2007.02.068 ↗
47. Dissolution enhancement of a model poorly water-soluble drug, atorvastatin, with ordered mesoporous silica: Comparison of MSF with SBA-15 as drug carriers10.1517/17425247.2015.1111335 ↗
48. Microsponge: An augmented drug delivery system
49. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan10.1016/j.ejps.2016.12.015 ↗
50. A G-quadruplex hydrogel via multicomponent self-assembly: Formation and zero-order controlled release10.1021/acsami.7b00957 ↗
51. Kinetic modeling on drug release from controlled drug delivery systems
52. In vitro drug release profiles of pH-sensitive hydroxyethylacryl chitosan/sodium alginate hydrogels using paracetamol as a soluble model drug10.1016/j.ijbiomac.2017.02.061 ↗